Crossmark

Sunitinib treatment reduces proinflammatory cytokine levels and mortality rates by suppressing the NLRP3 inflammasome signaling pathway in sepsis

Crossref DOI link: https://doi.org/10.1007/s10787-025-01862-3

Published Online: 2025-07-29

Published Print: 2025-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kucuk, Ahmet https://orcid.org/0009-0002-6421-6436
Aksungur, Nurhak https://orcid.org/0000-0003-4477-5775
Halici, Zekai https://orcid.org/0000-0001-6854-6059
Tavaci, Taha https://orcid.org/0000-0002-8284-8317
Ozkaraca, Mustafa https://orcid.org/0000-0001-9765-4569
Tebrizi, Behzat https://orcid.org/0000-0002-9075-7239
License Information

Text and Data Mining valid from 2025-07-29

Version of Record valid from 2025-07-29
More Information

Article History

Received: 31 May 2025

Accepted: 6 July 2025

First Online: 29 July 2025

Declarations

:

: The authors have disclosed that they do not have any potential conflicts of interest.